An international team led by University of British Columbia researcher Dr. Josef Penninger has found a trial drug that effectively blocks the cellular door SARS-CoV-2 uses to infect its hosts.
A new Cochrane Special Collection, COVID-19: Effective options for quitting smoking during the pandemic, published today in the Cochrane Library.
Updated CT scoring criteria that considers lobe involvement, as well as changes in CT findings (i.e., ground-glass opacity, crazy-paving pattern, and consolidation), could quantitatively and accurately evaluate the progression of coronavirus disease (COVID-19) pneumonia, according to an open-access article in the American Journal of Roentgenology. "The earlier that COVID-19 is diagnosed and treated, the shorter the time to disease resolution and the lower the highest and last CT scores are," concluded lead author Guoquan Huang.
The authors describe measures taken to reduce the risk of transmitting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to medical staff and cancer patients seeking treatment during the COVID-19 outbreak in China.
Developed by researchers at the Butantan Institute (Brazil) and Boston Children's Hospital, part of the Harvard Medical School (USA), the innovation is capable of providing protection against all serotypes of the bacterium Streptococcus pneumoniae.
Individuals taking a class of steroid hormones called glucocorticoids for conditions such as asthma, allergies and arthritis on a routine basis may be unable to mount a normal stress response and are at high risk if they are infected with the virus causing COVID-19, according to a new editorial published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.
Lessons learned from the 2003 severe acute respiratory syndrome (SARS) epidemic may help reduce the spread of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2), the cause of coronavirus disease 2019 (COVID-19), to health care workers performing open tracheostomies, a surgical procedure to open an airway that may be required for many patients with COVID-19.
UC Davis Health physicians and medical staff detail the diagnosis and treatment for first known case of community transmission of COVID-19 in the US. The case reveals how the patient's symptoms matched -- and sometimes varied from -- published studies of COVID-19 infection at the time.
Physicians, healthcare professionals, researchers, and patients are actively debating the potential influence of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in patients during the COVID-19 outbreak. In a new review published in Mayo Clinic Proceedings, a group of scientists who have been working on the frontlines fighting the deadly virus in Spain, Italy, and the United States, dissect the controversy in considerable detail, to explain the level of evidence on this topic for clinicians.
The direct oral anticoagulant rivaroxaban dramatically cut the likelihood of serious venous thromboembolism (VTE) in people recovering from lower limb orthopedic surgery requiring immobilization in comparison with enoxaparin, another anticoagulant agent, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).